If you have not heard about the upcoming Rocky Mountain Life Science Investor Conference at the Ritz Carlton – Denver on 17 September, yet, you sure will get an earful about it here at CLSDF. Today’s post particularly applies to those companies who have applied to present at the RMLSIC and were not selected as [...]

• 428http://clsdf.com/2009/08/the-best-200-you-can-spend-on-917/The+Best+%24200+You+Can+Spend+on+9%2F17%212009-08-31+15%3A14%3A00admin

FDA will seek input from the Oncologic Drugs Advisory Committee on Wednesday 2 September re: review of Allos Therapeutics’ (NASDAQ: ALTH) New Drug Application for pralatrexate (Folotyn); for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. It appears as though reviewers have questioned some findings reported by the Company on the effectiveness [...]

• 427http://clsdf.com/2009/08/allos-thx-he-said-she-said-monday%e2%80%a6/Allos+THx+%7C+He+Said%2C+She+Said+Monday%E2%80%A62009-08-31+15%3A07%3A00admin